Drug intelligence / Profile preview

NanoSTING-003

Development stage: Preclinical
Lead developer: AuraVax Therapeutics
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intranasal

Overview

NanoSTING-003 is an intranasal host-directed therapeutic (HDT) currently in preclinical development by AuraVax Therapeutics for the prevention and treatment of respiratory infections. The drug utilizes a nanoparticle delivery system to activate the Stimulator of Interferon Genes (STING) pathway directly within the respiratory tract. By targeting the host's innate immune system rather than the pathogen itself, NanoSTING-003 aims to stimulate local production of interferons and other immune mediators, providing broad-spectrum protection against a variety of respiratory viruses and bacteria. This approach is designed to enhance the body's natural defenses at the primary site of infection.

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on NanoSTING-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoSTING-003.

Explore the full profile